BIO-TECHNE Corp vs ProShares Ultra Semiconductors — how do they compare? BIO-TECHNE Corp trades at $71.63 (market cap $11.16B), while ProShares Ultra Semiconductors trades at $89.82. The key difference: BIO-TECHNE Corp pays a 0.45% dividend while ProShares Ultra Semiconductors pays none, and BIO-TECHNE Corp is trading nearer its 52-week high, ProShares Ultra Semiconductors nearer its low. Which is the better fit depends on your goals.
| TECH | USD | |
|---|---|---|
Market Cap | $11.16B | — |
Sector | Health | Leveraged / Inverse |
52-Week High | $72.12 | $113.53 |
52-Week Low | $43.31 | $39.58 |
Enterprise Value | $11.24B | — |
Dividend Yield | 0.45% | — |
Trailing returns across standard periods
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →USD is a leveraged ETF that seeks daily investment results, before fees and expenses, that correspond to two times (2x) the daily performance of the Dow Jones U.S. Semiconductors™ Index. It is a tactical instrument designed for sophisticated traders looking to magnify short-term bullish views on the U.S. semiconductor industry, specifically focusing on large-cap leaders in the chip and equipment space.
Read more on USD →